Trials / Completed
CompletedNCT00520936
A Study of Pemetrexed in Children With Recurrent Cancer
A Phase II Study of Pemetrexed in Children With Recurrent Malignancies
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 22 Years
- Healthy volunteers
- Not accepted
Summary
To determine the response rate of pemetrexed given every 21 days for the treatment of children with relapsed or refractory osteosarcoma, Ewing's sarcoma/peripheral primitive neuroectodermal tumors (PNET), rhabdomyosarcoma, neuroblastoma, ependymoma, medulloblastoma/supratentorial PNET or non-brain stem high-grade glioma.
Conditions
- Osteosarcoma
- Medulloblastoma
- Sarcoma, Ewing's
- Neuroblastoma (Measurable Disease)
- Neuroblastoma (Metaiodobenzylguanidine
- Positive Evaluable)
- Rhabdomyosarcoma
- Ependymoma
- Non-brainstem High-grade Glioma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pemetrexed | 1910 milligrams per meter squared (mg/m\^2) (or 60 milligrams per kilogram \[mg/kg\] if patient \<12 months old), intravenous (IV), for 21 days x 17 cycles |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2010-02-01
- Completion
- 2010-02-01
- First posted
- 2007-08-27
- Last updated
- 2011-02-25
- Results posted
- 2011-02-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00520936. Inclusion in this directory is not an endorsement.